Subcutaneous vedolizumab treatment for ulcerative colitis and Crohn‘s disease in clinical trial VISIBLE
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Lukáš M. Perspektivy biologické léčby u idiopatických střevních zánětů. Gastroent Hepatol 2014; 68 (3): 225–229.
2. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68 (6): 481–484. doi: 10.14735/amgh2014481.
3. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease. N Engl J Med 2013; 369 (8): 711–721. doi: 10.1056/NEJMoa1215739.
4. Sandborn WJ, Baert F, Danese S et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 2020; 158 (3): 562–572.e12. doi: 10.1053/j.gastro.2019.08.027.
5. Vermeire S, Sandborn W, Baert F et al. OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: results of the VISIBLE 2 study. J Crohns Colitis 2020; 14 (Suppl 1): S020–S021. doi: 10.1093/ecco-jcc/jjz203.022.
6. Loftus EV jr, Sandborn WJ, Wolf D et al. P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2. J Crohns Colitis 2019; 13 (Suppl 1): S361–S362. doi: 10.1093/ecco-jcc/ jjy222.623.
7. Sandborn WJ, Wolf D, D’haens G et al. P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: a post hoc analysis of the VISIBLE trial data. J Crohns Colitis 2020; 14 (Suppl 1): S442–S443. doi: 10.1093/ecco-jcc/jjz203.639.